White Papers
TrialCard
Since the end of the pharmaceutical industry’s “blockbuster era” and the beginning of its “specialty product era”, drug makers have used the term “hub services” to describe the often ponderous process of ranting patients access to critical medications. While the term itself … Read More »
ArcheMedX
Discover what you can do today to firmly establish your competitive advantage – to avoid being relegated to the sidelines. Will 2021 allow us to bid farewell to COVID-19? Whether we can eradicate this terrible virus or not, many of its impacts will persist. To assist Sponsor … Read More »
WCG
Targeted expertise when and where you need it: WCG Clinical Research Coordinators help equip sites to navigate the “new normal.”
TrialCard Incorporated
As the market landscape relative to co-pay assistance programs continues to evolve, it is important for biopharmaceutical manufacturers to have a practical strategy in place. This white paper provides valuable insight into planning for 2021 and beyond. TrialCard Incorporate … Read More »
Avant Healthcare
The defining medium of our age, social media has revolutionized the way we communicate, learn about the world, and organize ourselves into communities. For doctors and other HCPs, social media presents an unprecedented opportunity for engagement and collaboration that is sha … Read More »
ArcheMedX
A deer in the headlights. That’s an easy way to describe most sales leaders right now, as they formulate how they’re going to implement new “virtual selling” sales frameworks with their formerly “press the flesh” sales teams. But really – a year ago – if you’d suggested to m … Read More »
Elligo Health Research
As COVID-19 continues to disrupt clinical research, the consequences are poised to be devastating for sponsors, physicians, patients, and worldwide health. Elligo Health Research® is uniquely situated and experienced to support the continuation of effective clinical research … Read More »
Elligo Health Research
The disconnect between clinical research and medical care has become increasingly burdensome, especially in the wake of the COVID-19 pandemic. As clinical research sponsors continually seek ways to accelerate their trials while maintaining safety and quality, technology rema … Read More »
WCG
Infectious disease “challenge” studies, in which healthy participants are deliberately infected with pathogens to investigate the cause, prevention, and treatment of infectious diseases, hold great potential for delivering high-quality data about new interventions. Infectiou … Read More »
Clinical Ink
Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. The biggest challenge facing clinical research today is the need to gather, analyze, and report data. To collect patient data more efficiently, researchers are increasingly explorin … Read More »
TrialCard
Affordability programs, like co-pay programs, are highly effective at helping patients initiate therapy by reducing cost barriers. While they also improve fill rates incrementally, affordability programs only address the financial barriers to non-adherence without tackling t … Read More »
81qd
Susan Abedi shares how AI can be a positive disruptor for diagnosis – how to take advantage of its potential and engage effectively with HCPs and patients to shorten the time to diagnosis. She also covers how AI can raise awareness of the clinical journey. There is also a … Read More »
LexisNexis Risk Solutions
The world of medical claims data can be extremely complex. With over 100,000 ICD-10 diagnosis and CPT procedure codes currently in use, to wade through de-identified claims data often rests solely on the expertise of those who can confidently navigate vast amounts of big dat … Read More »
LexisNexis
View this informative infographic containing numerous statistics about influenza in the U.S.
Manatt Health
To help you manage effectively through the intricacies of 340B, Manatt Health has developed a 50-state survey on 340B, analyzing how states reimburse 340B covered entities and contract pharmacies for 340B drugs, and the steps states are taking to avoid duplicate discounts. D … Read More »
MicroMass Communications
“Behavioral science” is becoming a buzzword for pharma. Why? Because behavior is a barrier to meeting brand objectives. This barrier could be in the form of a patient’s adherence, a patient’s reluctance to start a new therapy, or even a healthcare provider’s clinical inertia … Read More »
MedSurvey
This white paper provides critical information about obstacles to continued oncology research and recommendations for effectively overcoming them. It first traces current and projected trends in the field of oncology and related market research. Next it presents key findings … Read More »
eClinical Solutions
Data from clinical trials is extremely valuable but often underutilized. This is typically the result of insufficient planning. Industry experts are frustrated knowing that stakeholders do not have sufficient access to their data, thus losing tremendous value since the data … Read More »
Avant Healthcare
Storytelling may seem like an antiquated tool in modern times, which is exactly what makes it so powerful. How? Life unfolds in the narratives we share with each other. A great story can go where quantitative analysis often cannot: straight to the heart. Clinical trial data … Read More »
HAVAS LYNX GROUP
This white paper explores how some of the world’s most innovative companies are bringing the patient experience front and centre in clinical trials, and reaping the benefits of doing so. From protocol design to recruitment and retention, it’s about seeing every touchpoint th … Read More »
Rx EDGE Media Network
In revolutions past, there have been moments when a seemingly singular entity or action emerges spontaneously and changes the existing course of action. But more often, it is multiple factors that coincide and work in tandem to comprehensively transform an entire industry or … Read More »
Wraser Pharmaceuticals
Sharp rises in opioid abuse and overdose rates in the United States over the past two decades have prompted much-needed review of prescription rates and ease of access to controlled substances. Combatting these alarming trends requires assessing which opioids are more addic … Read More »
WIRB Copernicus Group
The way site feasibility is conducted has changed over the years. The practice of mailing paper questionnaires and manually reviewing paper results is obsolete — even emailing surveys has become outdated. Sponsors have transitioned to cloud-based, site feasibility solutions … Read More »
Avant Healthcare
In the pharmaceutical world, the sales representative’s role interacting with HCPs—and their impact on those HCPs—has taken a hit. KOL interactions remain critically important to ensure HCP audiences receive the right message via the right channel at the right time. Take a f … Read More »
TrialCard
The incidences of pharmacy fraud involving pharmaceutical manufacturers’ co-pay card programs are on the rise. In this white paper, TrialCard discusses the steps it has taken to expand its Pharmacy Fraud Monitoring Service, which identifies fraud and greatly reduces the rei … Read More »
Mark Summers, WIRB Copernicus Group
Despite all the advances in science, medicine and technology, clinical trials are stuck in a rut: Most have trouble meeting enrollment targets. It’s an analog problem in a digital world. You could find hundreds, maybe thousands, of reasons why a specific study is slow to enr … Read More »
Blue Latitude Health
Healthcare markets are becoming more competitive and more complex, so how is this impacting the way pharma launches products and services? In this in-depth white paper, we explore the challenges and opportunities for pharma companies launching products and services today. By … Read More »
PharmaSeek
Over the years, studies have been conducted to ascertain the cost of research and development (“R&D”) required to bring a new drug to market. Experts disagree on the exact amount, but the consensus is that the figure is in the hundreds of millions to over a billion dolla … Read More »